Small molecular library screening in search of an IMP1 (IGF2BP1) inhibitor revealed a small molecule 2‐[(5‐bromo‐2‐thienyl) methylene]amino benzamide (BTYNB) with potent IMP1 inhibitory effect which inhibited proliferation of ovarian cancer and melanoma cells.[149] BTYNB reduces the proliferation of leukemia cells and induces their differentiation.[150] Increased IGF2BP2 in AML cells is associated with tumorigenesis and self‐renewal of leukemia stem cells. The gene discussed is IGF2BP2; the disease is ovarian carcinoma.